Impact of Anti–T-Cell Therapy in the Immunogenicity of Seasonal Influenza Vaccine in Kidney Transplant Recipients

• DOI: 10.1097/tp.0b013e31825f7f82
• Publication Date: 2012-08-15T08:57:35Z
• Authors: Angela Orcurto; Manuel Pascual; Katja Hoschler; Vincent Aubert; Pascal Meylan; Oriol Manuel
• Keywords: Thymoglobulin; Basiliximab; Seroconversion; Hemagglutination assay

The influence of anti-T-cell therapy in the immunogenicity influenza vaccine kidney transplant recipients remains unclear.During 2010 to 2011 season, we evaluated immune response inactivated trivalent having received Thymoglobulin or basiliximab as induction therapy. A hemagglutination inhibition assay was used assess vaccine. primary outcome geometric mean titers after vaccination.Sixty patients (Thymoglobulin n=22 and n=38) were included. Patients group older (P=0.16), showed higher creatinine levels (P=0.16) had more frequently a previous (P=0.02). There no significant differences for any three viral strains between groups (P=0.69 H1N1, P=0.56 H3N2, P=0.7 B strain). Seroconversion at least one strain seen 15 (68%) 22 28 (73%) 38 (P=0.77). In vaccinated during first year receiving (n=25), there trend toward lower responses group. who CD4(+) cell counts IgM, an average 16.2 months transplantation. multivariate analysis that only absence mycophenolate associated with better (odds ratio=9.47; 95% confidence interval, 1.03-86.9; P=0.047).No either basiliximab.